This file is part of IDEAS, which uses RePEc data


[ Papers | Articles | Software | Books | Chapters | Authors | Institutions | JEL Classification | NEP reports | Search | New papers by email | Author registration | Rankings | Volunteers | FAQ | Blog | Help! ]

Price Regulation of Drugs: Lessons from Germany

Author info | Abstract | Publisher info | Download info | Related research | Statistics
Author Info
Zweifel, Peter
Crivelli, Luca

Additional information is available for the following registered author(s):

Abstract

This paper purports to explain the pricing policy of pharmaceutical companies in Germany prior and after the introduction of reference prices (RP) in 1989. First, the threat of such regulation may have kept prices finite despite a completely insured market. Next, the pricing policies of both the producer of an innovative drug and of a competing generic under RP are predicted. These predictions are then confronted with actual pricing policy for three products in the guise of case studies. Finally, the impact of modified copayment rules on pricing decisions is analyzed. Copyright 1996 by Kluwer Academic Publishers

Download Info
To our knowledge, this item is not available for download. To find whether it is available, there are three options:
1. Check below under "Related research" whether another version of this item is available online.
2. Check on the provider's web page whether it is in fact available.
3. Perform a search for a similarly titled item that would be available.

Publisher Info
Article provided by Springer in its journal Journal of Regulatory Economics.

Volume (Year): 10 (1996)
Issue (Month): 3 (November)
Pages: 257-73
Download reference. The following formats are available: HTML (with abstract), plain text (with abstract), BibTeX, RIS (EndNote, RefMan, ProCite), ReDIF
Handle: RePEc:kap:regeco:v:10:y:1996:i:3:p:257-73

Contact details of provider:
Web page: http://www.springerlink.com/link.asp?id=100298

For technical questions regarding this item, or to correct its listing, contact: (Christopher F. Baum).

Related research
Keywords:

Other versions of this item:

Cited by:
(explanations, Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.)
  1. Peter Kotzian, 2002. "Stuck in the Middle: Welfare Effects of the European Pharmaceutical Markets' Incomplete Integration and a Possible Remedy," MZES Working Papers 59, MZES. [Downloadable!]
  2. Caroline Elliott & Melinda Acutt, 2007. "Antitrust Policy: The Impact of Revenue Penalties on Price," Experimental Economics, Springer, vol. 7(1), pages 1-8, March. [Downloadable!] (restricted)
    Other versions:
  3. Richter, Andreas & Weber, Frederik, 2009. "Mortality-Indexed Annuities," Discussion Papers in Business Administration 10994, University of Munich, Munich School of Management. [Downloadable!]
  4. Patricia M. Danzon & Jonathan D. Ketcham, 2003. "Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand," NBER Working Papers 10007, National Bureau of Economic Research, Inc. [Downloadable!] (restricted)
  5. John Yfantopoulos, 2008. "Pharmaceutical pricing and reimbursement reforms in Greece," The European Journal of Health Economics, Springer, vol. 9(1), pages 87-97, February. [Downloadable!] (restricted)
  6. Boris Augurzky & Silja Göhlmann & Stefan Greß & Jürgen Wasem, 2009. "Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach," Health Economics, John Wiley & Sons, Ltd., vol. 18(4), pages 421-436. [Downloadable!]
  7. Joan Ramon Borrell Arque, 2001. "Drug price differentials caused by de-listing and price cap policies," Working Papers in Economics 70, Universitat de Barcelona. Espai de Recerca en Economia.
  8. Carol A. Adams, Nongnooch Kuasirikun, 2000. "A comparative analysis of corporate reporting on ethical issues by UK and German chemical and pharmaceutical companies," European Accounting Review, Taylor and Francis Journals, vol. 9(1), pages 53-79, May. [Downloadable!] (restricted)
  9. Anna Merino, 2000. "The Impact of the Reference Price System on the Pharmaceutical Market: A Theoretical Approach," Economics Working Papers 524, Department of Economics and Business, Universitat Pompeu Fabra, revised Jun 2003. [Downloadable!]
  10. Jaume Puig, 2005. "The Impact of Generic Reference Pricing Interventions in the Statin Market," Working Papers, Research Center on Health and Economics 906, Department of Economics and Business, Universitat Pompeu Fabra. [Downloadable!]
  11. Guillem López & Jaume Puig, 1999. "Review of the Literature on Reference Pricing," Economics Working Papers 362, Department of Economics and Business, Universitat Pompeu Fabra. [Downloadable!]
  12. Caroline Elliott & Melinda Acutt, 2001. "Threat-based regulation and endogenously determined punishments," Working Papers 000040, Lancaster University Management School, Economics Department. [Downloadable!]
  13. Antonio Cabrales, 2003. "Pharmaceutical Generics, Vertical Product Differentiation, and Public Policy," Working Papers, Research Center on Health and Economics 662, Department of Economics and Business, Universitat Pompeu Fabra. [Downloadable!]
    Other versions:
  14. Anna Merino, 2000. "The Impact of the Reference Price System on the Pharmaceutical Market: A Theoretical Approach," Working Papers, Research Center on Health and Economics 524, Department of Economics and Business, Universitat Pompeu Fabra, revised Jun 2003. [Downloadable!]
  15. Guillem López & Jaume Puig, 1999. "Review of the Literature on Reference Pricing," Working Papers, Research Center on Health and Economics 362, Department of Economics and Business, Universitat Pompeu Fabra. [Downloadable!]
  16. Jaume Puig, 2005. "The Impact of Generic Reference Pricing Interventions in the Statin Market," Economics Working Papers 906, Department of Economics and Business, Universitat Pompeu Fabra. [Downloadable!]
  17. Nina Pavcnik, 2000. "Do Pharmaceutical Prices Respond to Insurance?," NBER Working Papers 7865, National Bureau of Economic Research, Inc. [Downloadable!] (restricted)
  18. Nell, Martin & Richter, Andreas & Schiller, Jörg, 2006. "When prices hardly matter: Incomplete insurance contracts and markets for repair goods," Discussion Papers in Business Administration 1187, University of Munich, Munich School of Management. [Downloadable!]
    Other versions:
  19. Jorge Mestre-Ferrandiz, 2000. "Reference Prices: The Spanish Way," UFAE and IAE Working Papers 481.01, Unitat de Fonaments de l'Anàlisi Econòmica (UAB) and Institut d'Anàlisi Econòmica (CSIC). [Downloadable!]
  20. Melinda Acutt & Caroline Elliott, 2001. "Threat-Based Competition Policy," European Journal of Law and Economics, Springer, vol. 11(3), pages 309-317, May. [Downloadable!] (restricted)
  21. Kurt R. Brekke & Astrid L. Grasdal & Tor Helge Holmås, 2007. "Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?," CESifo Working Paper Series CESifo Working Paper No. , CESifo Group Munich. [Downloadable!]
  22. Paul V. Grootendorst & John K. Marshall & Anne M. Holbrook & Lisa R. Dolovich & Bernie J. O'Brien & Adrian R. Levy, 2004. "The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs," Social and Economic Dimensions of an Aging Population Research Papers 115, McMaster University. [Downloadable!]
Statistics
Access and download statistics

Did you know? About five million pdf files are downloaded through RePEc every year.

This page was last updated on 2009-12-4.

This information is provided to you by IDEAS at the Department of Economics, College of Liberal Arts and Sciences, University of Connecticut using RePEc data on a server sponsored by the Society for Economic Dynamics.